• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • Clinical Trial Listings
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • Benchmark Reports
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » PDI, White House, CDC partner to combat antimicrobial resistance

PDI, White House, CDC partner to combat antimicrobial resistance

June 4, 2015
CenterWatch Staff

PDI, a U.S. healthcare company, has announced a series of corporate commitments designed to educate internal associates and customers about strategies to reduce the threat of antimicrobial-resistant microorganisms as part of its ongoing partnership with the U.S. Centers for Disease Control and Prevention (CDC) and in support of The White House's National Strategy to Combat Antibiotic-Resistant Bacteria.

"PDI plays an important role in helping to advance the discussion around antimicrobial resistance because our business is centered on eliminating antimicrobial-resistant bacteria before it enters the human body and becomes problematic," said Dr. Hudson Garrett, vice president of clinical affairs. "Unlike many others that are combating issues around antibiotic resistance in the body, we are trying to 'prevent' the problem at an earlier stage."

According to CDC estimates, antibiotic and antimicrobial resistance is responsible for as many as 2 million illnesses and 23,000 deaths annually. Through its ongoing work with the CDC and new partnership with the White House, PDI is focused on addressing the negative impact of deadly antibiotic-resistant bacteria—often called "superbugs"—with awareness initiatives across multiple facets of its business. This includes specific commitments that will:

  • Incorporate antimicrobial-resistance messaging into sales and marketing materials
  • Provide training and resources on core principles of antimicrobial resistance to PDI sales professionals, customer-facing associates and quality management associates
  • Facilitate regulatory and research development that prevents superbug development
  • Build clinical education resources for our customers.

    Upcoming Events

    • 16Oct

      MAGI@home Clinical Research Conference 2023

    • 25Oct

      2023 WCG Patient Forum

    • 26Oct

      FDA in 2024: What to Expect in an Election Year

    Featured Products

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    • Best Practices for Clinical Trial Site Management

      Best Practices for Clinical Trial Site Management

    Featured Stories

    • Donna Snyder

      New WCG Executive Physician Outlines Goals for Clinical Research

    • Hand Shake at Meeting

      Partnership to Bolster Trials in Low Resource Regions Kicks Off

    • Guidelines-360x240.png

      Major Industry Groups Offer Feedback on ICH’s E6(R3) Guidelines

    • AsktheExpertsBadge-360x240.png

      Ask the Experts: Monitoring

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell or Share My Data

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 703.538.7600 – Toll free 888.838.5578

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing